Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary Gintant

Showing results (1-10 of 40) with videos related to

Pageof 4
Sort By:
British Journal of Pharmacology|January 15, 2022
Assessing the fidelity of translation of non-clinical assays: a Pharma perspectiveGary Gintant
Journal of Cardiovascular Pharmacology|December 25, 2002
On a newly proposed in vitro proarrhythmia modelGary Gintant
British Journal of Pharmacology|July 11, 2012
Ions, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluationsGary Gintant
Handbook of Experimental Pharmacology|June 21, 2015
In Vitro Early Safety Pharmacology Screening: Perspectives Related to Cardiovascular SafetyGary Gintant
Pharmacology & Therapeutics|September 3, 2010
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongationGary Gintant
Expert Opinion on Drug Discovery|March 5, 2020
The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectationsGary Gintant, Martin Traebert
Nature Reviews. Drug Discovery|February 20, 2016
Evolution of strategies to improve preclinical cardiac safety testingGary Gintant, Philip T Sager, Norman Stockbridge
Cell Stem Cell|July 8, 2017
The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and DiscoveryGary Gintant, Bernard Fermini, Norman Stockbridge, et al.
Journal of Molecular and Cellular Cardiology|January 22, 2004
Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channelZhi Su, Ruth Martin, Bryan F Cox, et al.
Frontiers in Physiology|October 19, 2020
Identification of Drug-Induced Multichannel Block and Proarrhythmic Risk in Humans Using Continuous T Vector Velocity Effect Profiles Derived From Surface ElectrocardiogramsWerner Bystricky, Christoph Maier, Gary Gintant, et al.
Pageof 4

Showing results (1-10 of 40) with videos related to

Sort By:
Pageof 4
British Journal of Pharmacology|January 15, 2022
Assessing the fidelity of translation of non-clinical assays: a Pharma perspectiveGary Gintant
Journal of Cardiovascular Pharmacology|December 25, 2002
On a newly proposed in vitro proarrhythmia modelGary Gintant
British Journal of Pharmacology|July 11, 2012
Ions, equations and electrons: the evolving role of computer simulations in cardiac electrophysiology safety evaluationsGary Gintant
Handbook of Experimental Pharmacology|June 21, 2015
In Vitro Early Safety Pharmacology Screening: Perspectives Related to Cardiovascular SafetyGary Gintant
Pharmacology & Therapeutics|September 3, 2010
An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongationGary Gintant
Expert Opinion on Drug Discovery|March 5, 2020
The roles of human induced pluripotent stem cell-derived cardiomyocytes in drug discovery: managing in vitro safety study expectationsGary Gintant, Martin Traebert
Nature Reviews. Drug Discovery|February 20, 2016
Evolution of strategies to improve preclinical cardiac safety testingGary Gintant, Philip T Sager, Norman Stockbridge
Cell Stem Cell|July 8, 2017
The Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and DiscoveryGary Gintant, Bernard Fermini, Norman Stockbridge, et al.
Journal of Molecular and Cellular Cardiology|January 22, 2004
Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channelZhi Su, Ruth Martin, Bryan F Cox, et al.
Frontiers in Physiology|October 19, 2020
Identification of Drug-Induced Multichannel Block and Proarrhythmic Risk in Humans Using Continuous T Vector Velocity Effect Profiles Derived From Surface ElectrocardiogramsWerner Bystricky, Christoph Maier, Gary Gintant, et al.
Pageof 4